請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7826
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張書森 | |
dc.contributor.author | Kai-Ping Hu | en |
dc.contributor.author | 胡凱評 | zh_TW |
dc.date.accessioned | 2021-05-19T17:54:59Z | - |
dc.date.available | 2022-03-01 | |
dc.date.available | 2021-05-19T17:54:59Z | - |
dc.date.copyright | 2017-03-01 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-10-19 | |
dc.identifier.citation | Alfonso, V., Bermbach, N., Geller, J., & Montaner, J. S. (2006). Individual variability in barriers affecting people's decision to take HAART: a qualitative study identifying barriers to being on HAART. AIDS Patient Care & STDs, 20(12), 848-857.
Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care: does it matter?. Journal of health and social behavior, 1-10. Babbie, E. R. (2013). The basics of social research. Cengage Learning. Barbaro, G; Barbarini, G (December 2011). 'Human immunodeficiency virus & cardiovascular risk'. The Indian journal of medical research 134 (6): 898–903. Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., . . . Sudre, P. (1999). Why Is Highly Active Anti-retroviral Therapy (HAART) Not Prescribed or Discontinued? JAIDS Journal of Acquired Immune Deficiency Syndromes, 21(2), 114-119. Bronfenbrenner, U. (1999). Environments in developmental perspective: Theoretical and operational models. Measuring environment across the life span: Emerging methods and concepts, 3-28. Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., . . . Team, H. S. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 365(6), 493-505. doi:10.1056/NEJMoa1105243 Coleman, C. L., Holzemer, W. L., Eller, L. S., Corless, I., Reynolds, N., Nokes, K. M., . . . Hamilton, M. J. (2006). Gender differences in use of prayer as a self-care strategy for managing symptoms in African Americans living with HIV/AIDS. J Assoc Nurses AIDS Care, 17(4), 16-23. doi:10.1016/j.jana.2006.05.005 Cooper, V., Buick, D., Horne, R., Lambert, N., Gellaitry, G., Leake, H., & Fisher, M. (2002). Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study. AIDS care, 14(3), 319-328. Dowshen, N., Lee, S. S., Castillo, M., Hawkins, L., & Barg, F. K. (2016). Barriers and Facilitators to HIV Prevention, Testing, and Treatment among Young Transgender Women. Journal of Adolescent Health, 58(2), S81-S82. Fang, C. T., Chang, Y. Y., Hsu, H. M., Twu, S J., Chen, K. T., Lin, C. C., et al. (2007). Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy monthly. Journal of the Association of Nurses in AIDS Care, 100 (2), 97-105. Fehr, J., Nicca, D., Goffard, J. C., Haerry, D., Schlag, M., Papastamopoulos, V., . . . Ledergerber, B. (2016). Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. Infection, 1-9. doi:10.1007/s15010-016-0887-x Gardner, E. M., McLees, M. P., Steiner, J. F., Del Rio, C., & Burman, W. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis, 52(6), 793-800. doi:10.1093/cid/ciq243 Gebremariam, M. K., Bjune, G. A., & Frich, J. C. (2010). Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health, 10(1), 651. doi:10.1186/1471-2458-10-651 Gellaitry, G., Cooper, V., Davis, C., Fisher, M., Leake Date, H., & Horne, R. (2005). Patients’ perception of information about HAART: impact on treatment decisions. AIDS care, 17(3), 367-376. Glass, T. A., & McAtee, M. J. (2006). Behavioral science at the crossroads in public health: extending horizons, envisioning the future. Social science & medicine, 62(7), 1650-167 Gold, R. S., Hinchy, J., & Batrouney, C. G. (2000). The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. International journal of STD & AIDS, 11(6), 361-370. Govindasamy, D., Ford, N., & Kranzer, K. (2012). Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS, 26(16), 2059-2067. doi:10.1097/QAD.0b013e3283578b9b Group, I. S. S., Lundgren, J. D., Babiker, A. G., Gordin, F., Emery, S., Grund, B., . . . Neaton, J. D. (2015). Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med, 373(9), 795-807. doi:10.1056/NEJMoa1506816 Group, T. A. S., Danel, C., Moh, R., Gabillard, D., Badje, A., Le Carrou, J., . . . Anglaret, X. (2015). A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med, 373(9), 808-822. doi:10.1056/NEJMoa1507198 Guba, E. & Linclon,Y. (1999). Establishing trustworthiness in A. Bryman & R.G Burgess (Eds.), Qualitative Research, vol. 3 (pp.397-444). London, Thousand Oaks California and New Delhi: Sage Publications. Hall, B. J., Sou, K. L., Beanland, R., Lacky, M., Tso, L. S., Ma, Q., ... & Tucker, J. D. (2016). Barriers and Facilitators to Interventions Improving Retention in HIV Care: A Qualitative Evidence Meta-Synthesis. AIDS and Behavior, 1-13. Hammer, S. M. (2011). Antiretroviral treatment as prevention. New England Journal of Medicine, 365(6), 561-562. Holtgrave, D. R., Maulsby, C., Wehrmeyer, L., & Hall, H. I. (2012). Behavioral factors in assessing impact of HIV treatment as prevention. AIDS Behav, 16(5), 1085-1091. doi:10.1007/s10461-012-0186-1 Hua, J., Emrick, C. B., Golin, C. E., Liu, K., Pan, J., Wang, M., . . . Jiang, N. (2014). HIV and stigma in Liuzhou, China. AIDS Behav, 18 Suppl 2(2), S203-211. doi:10.1007/s10461-013-0637-3 Hung, C., Hsiao, C., Chen, M., Hsieh, S., Chang, S., Sheng, W., ... & Chang, S. (2006). Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan. Japanese journal of infectious diseases, 59(4), 222. Insight Start Study Group. (2015). Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med, 2015(373), 795-807. Katz, I. T., Ryu, A. E., Onuegbu, A. G., Psaros, C., Weiser, S. D., Bangsberg, D. R., & Tsai, A. C. (2013). Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. Khoury, Z., Silva, R. S., & Villela, W. (2015). Factors associated with a delay in seeking HIV/AIDS treatment in Sao Paulo, Brazil. AIDS Behav, 19(4), 679-683. doi:10.1007/s10461-014-0885-x Klitzman, R., Kirshenbaum, S., Dodge, B., Remien, R., Ehrhardt, A., Johnson, M., . . . Kelly, J. (2004). Intricacies and inter-relationships between HIV disclosure and HAART: A qualitative study. AIDS care, 16(5), 628-640. Kremer, H., Ironson, G., Schneiderman, N., & Hautzinger, M. (2006). To take or not to take: decision-making about antiretroviral treatment in people living with HIV/AIDS. AIDS Patient Care & STDs, 20(5), 335-349. Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., . . . Mayer, K. H. (2005). Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS, 19(8), 526-537. doi:10.1089/apc.2005.19.526 Kvale, S. (2007). Contradictions of assessment for learning in institutions of higher learning. Rethinking assessment in higher education: Learning for the longer term, 57-71. Langebeek, N., Gisolf, E. H., Reiss, P., Vervoort, S. C., Thora, B., Richter, C., . . . Nieuwkerk, P. T. (2014). Predictors and correlates of adherence to combination antiretroviral therapy (cART) for chronic HIV infection: a meta-analysis. BMC medicine, 12(1), 142. Lew‐Ting, C. Y., & Chen, L. H. (2008). The surrogate marker and its discontents: pluralism in immunity maintenance among HIV‐infected persons in Taiwan. Sociology of health & illness, 30(7), 1039-1054. Lindbladh, E., & Lyttkens, C. H. (2002). Habit versus choice: the process of decision-making in health-related behaviour. Soc Sci Med, 55(3), 451-465. doi:http://dx.doi.org/10.1016/S0277-9536(01)00180-0 Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., . . . Cooper, C. (2006). Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med, 3(11), e438. doi:10.1371/journal.pmed.0030438 Palella Jr, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., ... & Holmberg, S. D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338(13), 853-860. Palmisano, L., & Vella, S. (2011). A brief history of antiretroviral therapy of HIV infection: success and challenges. Annali dell'Istituto superiore di sanitA, 47(1), 44-48. Patton, M. Q. (1990). Qualitative evaluation and research methods . SAGE Publications, inc. Posse, M., Meheus, F., van Asten, H., van der Ven, A., & Baltussen, R. (2008). Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health, 13(7), 904-913. doi:10.1111/j.1365-3156.2008.02091.x Remien, R. H., Hirky, A. E., Johnson, M. O., Weinhardt, L. S., Whittier, D., & Le, G. M. (2003). Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS and Behavior, 7(1), 61-72. Robertson, A. (1998). Shifting Discourses on Health in Canada: From Health Promotion to Population Health. Health Promotion International, 13(2), 155-166. doi:10.1093/heapro/13.2.155 Siedner, M. J., Ng, C. K., Bassett, I. V., Katz, I. T., Bangsberg, D. R., & Tsai, A. C. (2015). Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clinical Infectious Diseases, 60(7), 1120-1127. Sweeney, S. M., & Vanable, P. A. (2016). The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature. AIDS Behav, 20(1), 29-50. doi:10.1007/s10461-015-1164-1 van der Straten, A., Stadler, J., Luecke, E., Laborde, N., & Hartmann, M. (2014). Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. OPEN ACCESS OPEN ACCESS. Wei, C., Yan, H., Yang, C., Raymond, H. F., Li, J., Yang, H., . . . Stall, R. (2014). Accessing HIV testing and treatment among men who have sex with men in China: a qualitative study. AIDS care, 26(3), 372-378. Yegidis, B., Weinbach, R., Myers, L. (2012). Research Methods for Social Workers, Seventh Edition., Pearson Education. Centers for Disease Control and Prevention (CDC USA),2016, About HIV/AIDS (2016.08.31 revision).http://www.cdc.gov/hiv/basics/whatishiv.html UNAIDS. (2000). HIV and AIDS-related Stigmatization, Discrimination and Denial: Forms, Contexts and Determinants. Research Studies from Uganda and India.Geneva, UNAIDS. UNAIDS (Joint United Nations Programme on HIV/AIDS). AIDS epidemic update, 2009. UNAIDS. (2011). Global Report: UNAIDS Report on The Global AIDS Epidemic 2010. UNAIDS. (2014). Global Report: UNAIDS Report on The Global AIDS Epidemic 2013. WHO. (2009). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO. (2013). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO. (2015). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 丁文、丁志音、王永衛、余玉眉等(2009),我國愛滋病防治政策建議書 方啟泰. (2003).《全面雞尾酒療法政策對臺灣愛滋病疫情影響的實證研究》。行政院衛生署疾病管制局九十二年度科技研究發展計畫,計畫編號:DOH92-DC-1032。 呂昶賢、林宜慧(2007),不只是醫病—台灣愛滋感染者的醫療現況。 林正鄆. (2011). 男同性戀愛滋感染者就醫就業障礙與因應方式之初探. (碩士), 國立臺灣師範大學, 台北市. 陳向明(2002),社會科學質的研究。臺北:五南 陳遵宇(2013)〈台灣愛滋防治政策中的生命政治〉,《文化研究雙月報》,140:2-21。 陳馨傑. (2011). 男同志HIV感染者的帶病生涯與自我照顧. (碩士), 國立陽明大學, 台北市. 傅凱群. (2014). 風險評估 談愛滋感染者的服藥決策. 潘柏翰. (2015). 愛滋病個案管理師管理技巧及其與感染者關係初探-以輔導感染者自我健康為例. 臺灣大學健康政策與管理研究所學位論文, 1-116. 潘淑滿(2003),質性研究:理論與應用。臺北:心理。 楊世仰,2007,《HIV/AIDS相關資料庫分析五年計畫》。行政院衛生署疾病管制局九十六年度科技研究發展計畫,計畫編號:DOH 96-DC-2028。 謝佳吟, & 柯乃熒. (2010). 增強愛滋病毒感染者服用高效能抗反轉錄病毒藥物治療的動機. 愛之關懷季刊, (73), 30-36. 羅一鈞, 巫沛瑩, 劉玟君, & 張上淳. (2008). 台灣男同志愛滋病毒感染者延遲診斷之危險因子研究. 疫情報導, 24(11), 813-825. 行政院衛生署疾病管制局(2006),愛滋病檢驗及治療指引(第一版)。 行政院衛生署疾病管制局(2008),愛滋病檢驗及治療指引(第二版)。 行政院衛生署疾病管制局(2010),愛滋病檢驗及治療指引(第三版)。 行政院衛生福利部疾病管制署 (2013),陽性預防:男同志愛滋感染者之安全性行為與服藥順從性第二年計畫 行政院衛生署疾病管制局(2013) ,HIV/AIDS 相關資料庫分析五年計畫 行政院衛生署疾病管制局(2013),愛滋病檢驗及治療指引(第四版)。 行政院衛生署疾病管制局(2015),人類免疫缺乏病毒傳染防治及感染者權益保障條例。 行政院衛生署疾病管制局(2015),傳染病介紹:人類免疫缺乏病毒感染 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7826 | - |
dc.description.abstract | 背景:根據衛生福利部疾病管制局截至2016年6月之統計,全台灣已知的累積愛滋感染者共有32,237名,存活人數(含發病者)計有26,898人,而每年約新增2000例感染者,存活感染者中約有近五千多名未接受治療,佔總感染人數之二至三成,因此,如何提升治療人數為防治愛滋病之重要議題。既有流行病學文獻指出,儘早服用抗逆轉錄病毒藥物,能夠有效降低愛滋感染者體內的病毒量,提升免疫力,與改善整體健康和生活品質;另外,穩定接受治療、且血中無法測得病毒的愛滋感染者,與沒有治療者相較下,傳染性大幅降低。2015年世界衛生組織(World Health Organization,WHO)公布最新的愛滋感染者治療指引,其中最重大的改變,便是將成人的建議治療範圍放寬:前版指引為感染者體內之CD4+細胞數量小於500cells/μL才建議接受治療,新版更改為「所有的感染者」都應接受治療(即不論其CD4+細胞數目之高低),對於感染者的服藥決策將造成重大影響。
近年來,聯合國愛滋病組織(UNAIDS)提出目標希望在2020年達到「90-90-90」,即90%感染者知道自己病況、90%知道病況者服用藥物、90%服用藥物者成功抑制病毒量,符合「以治療作為預防(TasP)」的原則。過去國外針對感染者服藥因素之研究,曾指出若干重要因素,如經濟、個人因素、藥物與醫療信念、日常計畫,以及人際關係等,經濟因素尤為關鍵。然而,台灣過去相關研究主要著重於服藥遵從性,甚少將影響開始服藥的因素作為主題。同時,由於台灣全面補助抗逆轉錄病毒藥物的政策,免除了經濟障礙,也讓感染者的主要考量因素,必定有別於國外研究結果。 目的:瞭解台灣愛滋感染者在確認感染後,接受或拒絕服用藥物治療之影響因素。 方法:本研究為探索感染者決定服藥與否之因素的質性研究。採深度訪談方法收集資料,以滾雪球與公開招募方式訪談21位愛滋感染者,3位醫療服務人員。感染者條件為:20歲以上、愛滋感染確診者;相關醫療人員則為20歲以上、曾照護愛滋感染者之醫療人員,包括感染科醫師與個案管理師。研究者將訪談內容錄音檔轉錄成逐字稿後,依據Strauss 和Corbin(1997)提出的開放性譯碼(open coding)原則來分析資料。 結果:影響感染者服藥意願之因素可劃分為三個層次,分別為個體、人際,與環境結構層次。同時,這些因素又會因生命歷程而改變,亦即為時間軸的面向。在三個層次當中,主要的影響因素分別是:(1)自覺健康(個體層次):感染者以其對身體健康與感染狀態之知覺、感受,或是生物性替代指標(CD4+細胞數量)來判斷自身健康狀態,當自認為健康良好狀態,或是不願接受自身感染狀態時,會有較大的傾向決定不接受服藥治療;(2)隱私問題(人際層次):多數感染者會盡量避免感染事實曝光,而抗愛滋藥物的外觀、每天固定服藥的舉動,以及就醫所留下的服藥紀錄,皆可能暴露感染身份,因此感染者會以此為考量拒絕接受治療;(3)醫療環境(環境結構層次):外在環境所帶來的醫療經驗,將會進而影響其服藥意願;良好友善的醫療環境與醫病關係,會使感染者對於醫療人員產生更多的信任,並進而與之討論自身狀況,而協商出適合感染者的治療方案;反之若為負面經驗,則會促使感染者對醫療體系產生排斥,進而不願就診與接受治療。 結論:本研究透過深度訪談,發掘影響台灣愛滋感染者服藥意願的主要因素,包括自覺健康、隱私問題、與醫病關係等;國外研究中所強調的經濟因素只影響少數弱勢受訪者的服藥意願。在防治策略上,可建立暢通的資訊管道、對愛滋友善的社會風氣、良好的醫病關係,並幫助弱勢感染者有更穩定的生活,以期感染者能更周全、真實、與具體地瞭解自身的健康狀態、病毒對健康造成的影響,以及藥物治療的效益與可能副作用。這些策略可望減少感染者接受藥物治療的阻礙,使其有較高意願決定接受治療。 | zh_TW |
dc.description.abstract | Background: According to Centers for Disease Control, a total of 32,237 human immunodeficiency virus (HIV)-positive cumulative cases have been reported in Taiwan as of June 2016, and the number of live patients (including those with Acquired Immune Deficiency Syndrome [AIDS]) is 26,898, while there are about 2,000 new cases every year. Among live patients approximately 5,000 did not receive treatment, accounting for around 20-30% of all live patients. To increase the number of HIV-positive patients who receive treatment is therefore an important issue. According to epidemiological literature, the early use of antiretroviral drugs can effectively reduce the amount of HIV virus in the body, enhance patient immunity and significantly contribute to health and better quality of life. In addition, comparing with those who do not receive treatment, the infectious ability of HIV-positive patients who receive stable treatment and have non-detectable level of virus amount reduce significantly. In 2015, the World Health Organization (WHO) released the latest guidelines on the treatment of HIV/AIDS. The most vital change is to loosen the recommended therapeutic range for adults. The original criterion was that antiretroviral treatment was recommended for patients with a level of CD4+ cells less than 500 cells/μL, and this was changed to “all HIV-positive patients should be treated (regardless of the level of CD4+ cells)”. This change would nevertheless significantly impact on decision-making about receiving treatment among patients. In recent years, the Joint United Nations Program on HIV and AIDS (UNAIDS) announced it goal to achieve “90-90-90” by 2020. That means by 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy; and 90% of all people receiving antiretroviral therapy will have viral suppression, to conform to the principle of “Treatment as prevention (TasP)”. Past international research on the factors influencing the decision to receive antiretroviral treatment has pointed out the importance of several factors, such as economic factors, individual factors, drug and medical beliefs, daily plans, and interpersonal relationships. Especially, the economic factors are shown to be particularly critical. In Taiwan, related previous studies have mainly focused on medication adherence rather than to decision to receive and initiate treatment. At the same time, the Taiwanese government has implemented the policy of comprehensive subsidy of the anti-retroviral drugs, which would not only eliminate the economic barriers to receiving treatment but also make different considerations among HIV-positive patients regarding receiving treatment from those shown in international research results.
Object: The aim of this study was to understand factors influencing the decision to receive or refuse antiretroviral treatment among patients with HIV in Taiwan. Methods: We conducted a qualitative study to explore the factors influencing HIV-positive patients’ decision to receive or refuse antiretroviral treatment. By using in-depth interview method to collect data, we interviewed 21 HIV-positive patients and three medical professionals with snowball sampling and open recruitment. The inclusion criteria for HIV-positive patients included an age of 20 years or older and a confirmed diagnosis of HIV infection; those for medical professionals (infectious disease specialists or specialized case managers of HIV-positive patients) included an age of 20 years or older and past experiences of providing care for HIV-positive patients. The interviews were transcribed into verbatim transcripts and analyzed according to the open coding principle proposed by Strauss and Corbin (1997). Result: Factors that affect the patients’ willingness to receive treatment could be assigned into three levels, i.e. individual, interpersonal, and environmental / structural levels. These factors would also evolve and change over the life course, namely an additional time dimension. At each of three levels, the most important factors were: (1) self-perceived health (individual level): patients judged their own health status according to their perception, feeling, or biologic substitute index (CD4+ cell number). When patients considered themselves healthy or in good health condition, or they tended to deny or ignore their own infection status, they would tend to decide not to receive treatment; (2) privacy protection issue (interpersonal level): most patients made efforts to hide their infection from being exposed to other people. However, the possession of antiretroviral medications, taking the medications in front of others, and the medical records are likely to expose their infection status. Therefore, they would refuse to receive treatment as a result of this concern; (3) medical service environment (environmental / structural level): experiences of interacting with medical professionals would impact on patients’ decision to receive treatment. Positive experiences, friendly environment, and good doctor–patient relationship would result in more trust in health care providers and allow them opportunities to discuss their concerns with health care providers; the process would then contribute to agreed and appropriate treatment plans for patients. On the contrary, negative experiences will lead to rejection toward health care system, loss of follow-up, and treatment refusal. Conclusion: In this study we conducted in-depth interviews to identify major factors influencing the decision to receive antiretroviral treatment among HIV-positive patients in Taiwan and found the importance of self-perceived health, privacy concerns, and doctor-patient relationship. The economic factors that were emphasized in the international research had an impact only among a small number of disadvantaged patients. Regarding prevention and control strategies, we can strive to develop channels for unimpeded dissemination of information, an HIV friendly social atmosphere, good doctor-patient relationships, and adequate support for patients with a deprived socioeconomic condition, with an aim to help patients to develop a more comprehensive understanding into their health status based on unbiased information, the true impact of the virus on their health, and the benefits and and potential side effects of the treatment. It is expected that these strategies could reduce the barriers and enhance the willingness of receiving antiretroviral treatment among HIV-positive patients. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:54:59Z (GMT). No. of bitstreams: 1 ntu-105-R03848020-1.pdf: 1932407 bytes, checksum: 023b15d73483d6b9684da3e96a27b149 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 摘要 i
Abstract iii 表目錄 ix 圖目錄 x 第壹章 緒論 1 第一節 研究背景與動機 1 第二節 研究目的 4 第三節 研究重要性 4 第貳章 文獻回顧 7 第一節 HIV/AIDS和其治療方式的簡介 8 第二節 國內外目前流行病學與治療現況 11 第三節 治療指引的演變歷史 15 第四節 影響服藥決策的因素 18 第五節 文獻小結 21 第參章 研究方法 23 第一節 研究設計 23 第二節 研究對象 25 第三節 研究工具 27 第四節 資料處理 28 第五節 研究的信效度與倫理 28 第肆章 研究發現 31 第一節 感染者個體層次之因素 32 第二節 人際關係層次之因素 44 第三節 外部結構環境層次之因素 49 第四節 時間變化之因素 54 第伍章 研究討論 56 第一節 與過往研究之比較 56 第二節 不同層次的因素如何互相影響 60 第三節 時間與疾病歷程對不同因素的影響 63 第四節 研究限制 65 第陸章 結論與建議 67 第一節 結論 67 第二節 研究建議 68 參考文獻 70 附件一、受訪者招募說明 76 附件二、訪談大綱 78 | |
dc.language.iso | zh-TW | |
dc.title | 影響愛滋感染者服藥意願之因素初探:質性研究 | zh_TW |
dc.title | An Exploratory Study of Factors Influencing the Decision to Start Antiretroviral Treatment Among People with HIV/AIDS: A Qualitative Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鍾道詮,張玨 | |
dc.subject.keyword | 愛滋,感染者,服藥意願,自覺健康,醫病關係, | zh_TW |
dc.subject.keyword | AIDS,HIV positive,willingness to take drugs,self-perceived health,doctor-patient relationship, | en |
dc.relation.page | 79 | |
dc.identifier.doi | 10.6342/NTU201603667 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2016-10-19 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf | 1.89 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。